Monogenic Diabetes Not Caused By Mutations in Mody Genes: A Very Heterogenous Group of Diabetes

Abstract

Monogenic diabetes represents a heterogeneous group of disorders resulting from a single gene defect leading to disruption of insulin secretion or a reduction in the number of beta cells. Despite the classification of monogenic diabetes into neonatal diabetes or maturity onset diabetes of the young (MODY) according to age of onset, not every case can be classified into those 2 groups. We evaluated patients with monogenic diabetes diagnosed during the last 10 year period. Type 1 DM, MODY, and patients with negative autoantibodies and no mutation in a known gene were excluded from the study. Thirteen patients were diagnosed with monogenic diabetes in Department of Pediatric Endocrinology, Ankara University School of Medicine, Ankara, Turkey. Five of them were diagnosed after 6 months of age. Five had a KATP channel defect. Mutations in genes resulting in destruction of beta cells were detected in 7 patients, with 4 cases having a WFS, 2 an LRBA, and one a IL2RA mutation. Additional systemic findings were seen in 6/13 patients, with 5/6 having severe immune system dysfunction. Treatment with sulphonylurea was successful in two patients.. The other patients were given insulin in differing doses. Four patients died during follow-up, three of which had immune system dysfunction. Monogenic diabetes can be diagnosed after 6 months of age, even with positive autoantibodies. Immune dysfunction was a common feature in our cohort and should be investigated in all patients with early-onset monogenic diabetes. Mortality of patients with monogenic diabetes and additional autoimmunity was high in our cohort and is likely to reflect the multisystem nature of these diseases.

Key words

Monogenic diabetes - childhood - LRBA - Il2RA - WFS1

• References

• 1 Schwitzgebel VM. Many faces of monogenic diabetes. J Diabetes Investig 2014; 5: 121-133
• 2 Polak M, Dechaume A, Cavé H. et al. Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group. Diabetes 2008; 57: 1115-1119.3
• 3 Rubio-Cabezas O, Ellard S. Diabetes mellitus in neonates and infants: genetic heterogeneity, clinical approach to diagnosis, and therapeutic options. Horm Res Paediatr 2013; 80: 137-146
• 4 Greeley SA, Tucker SE, Worrell HI. et al. Update in neonatal diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 13-19
• 5 De Franco E, Flanagan SE, Houghton JA. et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet 2015; 386: 957-963
• 6 Rubio-Cabezas O, Hattersley AT, Njølstad PR. et al. ISPAD Clinical Practice Consensus Guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2014; 15 (Suppl. 20) 47-64
• 7 Shields BM, Hicks S, Shepherd MH. et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing?. Diabetologia 2010; 53: 2504-2508
• 8 Vaxillaire M, Froguel P. Monogenic diabetes: Implementation of translational genomic research towards precision medicine. J Diabetes 2016; 8: 782-795
• 9 Beltrand J, Elie C, Busiah K. et al. Sulfonylurea therapy benefits neurological and psychomotor functions in patients with neonatal diabetes owing to potassium channel mutations. Diabetes Care. 2015; 38: 2033-2041
• 10 Siklar Z, Ellard S, Okulu E. et al. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant. J Pediatr Endocrinol Metab 2011; 24: 1077-1080
• 11 Delvecchio M, Mozzillo E, Salzano G. et al. Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetes (ISPED). Monogenic Diabetes Accounts for 6.3% of Cases Referred to 15 Italian Pediatric Diabetes Centers During 2007 to 2012. J Clin Endocrinol Metab 2017; 102: 1826-1834
• 12 Fendler W, Borowiec M, Baranowska-Jazwiecka A. et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. Diabetologia 2012; 55: 2631-2635
• 13 Colclough K, Bellanne-Chantelot C, Saint-Martin C. et al Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat. 2013; 34: 669-685
• 14 Boutzios G, Livadas S, Marinakis E. et al. Endocrine and metabolic aspects of the Wolfram syndrome. Endocrine 2011; 40: 10-13
• 15 Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep 2016; 16: 6
• 16 Kumar S. Wolfram syndrome: important implications for pediatricians and pediatric endocrinologists. Pediatr Diabetes. 2010; 11: 28-37
• 17 Marshall BA, Permutt MA, Paciorkowski AR. et al. Phenotypic characteristics of early Wolfram syndrome. Orphanet J Rare Dis. 2013; 8: 64
• 18 Caudy AA, Reddy ST, Chatila T. et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007; 119: 482-487
• 19 Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr. 2013; 25: 708-714
• 20 Alroqi FJ, Chatila TA. T Regulatory Cell Biology in Health and Disease. Curr Allergy Asthma Rep. 2016; 16: 27
• 21 Siklar Z, Karataş D, Doğu F. et al. İkincioğulları A, Berberoğlu M. Regulatory T Cells and Vitamin D Status in Children with Chronic Autoimmune Thyroiditis. J Clin Res Pediatr Endocrinol 2016; 8: 276-281
• 22 Gámez-Díaz L, August D, Stepensky P. et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 2016; 137: 223-230
• 23 Serwas NK, Kansu A, Santos-Valente E. et al. Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype. Inflamm Bowel Dis. 2015; 21: 40-47
• 24 Charbonnier LM, Janssen E, Chou J. et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol. 2015; 135: 217-227
• 25 Alkhairy OK, Abolhassani H, Rezaei N. et al. Spectrum of Phenotypes Associated with Mutations in LRBA. J Clin Immunol 2016; 36: 33-45
• 26 Goudy K, Aydin D, Barzaghi F. et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol 2013; 146: 248-261
• 27 Sharfe N, Dadi HK, Shahar M. et al. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci 1997; 94: 3168-3171
• 28 Lo B, Zhang K, Lu W. et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 2015; 349: 436-440
• 29 Hanna S, Etzioni A. Leukocyte adhesion deficiencies. Ann N Y Acad Sci 2012; 1250: 50-55